ODT in BE study [Design Issues]

posted by Farmacevt – North Macedonia, 2022-01-18 17:01 (1231 d 05:54 ago) – Posting: # 22732
Views: 3,187

Dears,

I would appreciate if you can share your opinion regarding this particular case:

IF you develop generic orodispersible tablet (ODT) and the reference formulation is immediate release tablet (obviously it can be administrate only with water) is it enough to perform two way cross-over study where the ODT will be administrated without water and the reference tbl. with water, or 3 arm study (ODT administrated in both ways with and without water and the reference with water) should be performed?


Thank you

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,682 registered users;
26 visitors (0 registered, 26 guests [including 15 identified bots]).
Forum time: 23:56 CEST (Europe/Vienna)

EMEA. The European Medicines Evaluation Agency.
The drug regulatory agency of the European Union.
A statistician-free zone.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5